Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic Cancer

NAUnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 17, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Genetic ChangeChemotherapy EffectPancreatic Cancer
Interventions
DIAGNOSTIC_TEST

next generation sequencing

the investigator will compare genetic mutation between responder and non-responder using next generation sequencing examination.

DIAGNOSTIC_TEST

following next generation sequencing

The patient will be examined next generation sequencing before changing palliative chemotherapy for non-responders.

Trial Locations (1)

05505

RECRUITING

Asan medical center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT04110769 - Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic Cancer | Biotech Hunter | Biotech Hunter